skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Inhibition by progesterone of radiation-estrogen-induced mammary cancer in the rat

Abstract

The data from this preliminary experiment make it appear that continuous administration of progesterone protects animals from the synergism between estrogen and radiation. However, it also appears that the progesterone has by itself a protective effect against the individual carcinogenic agents since fewer tumors occurred on the opposite side as well as on the radiated side. In this preliminary experiment none of the animals that bore just progesterone pellets and were radiated developed mammary carcinomata. (auth)

Authors:
Publication Date:
Research Org.:
Alton Ochsner Medical Foundation, New Orleans
OSTI Identifier:
4365356
NSA Number:
NSA-29-008011
Resource Type:
Journal Article
Resource Relation:
Journal Name: Cancer Res., v. 33, no. 5, pp. 1136-1137; Other Information: Orig. Receipt Date: 30-JUN-74
Country of Publication:
Country unknown/Code not available
Language:
English
Subject:
N48520* -Life Sciences-Radiation Effects on Animals- Vertebrates; *ESTROGENS- CARCINOGENESIS; *NEOPLASMS- RADIOINDUCTION; *PROGESTERONE- RADIOSENSITIVITY EFFECTS; BIOLOGICAL RADIATION EFFECTS; IONIZING RADIATIONS; MAMMARY GLANDS; PARTIAL BODY IRRADIATION; RADIOSENSITIVITY EFFECTS; RATS; RESPONSE MODIFYING FACTORS; SYNERGISM RADIOINDUCTION

Citation Formats

Segaloff, A. Inhibition by progesterone of radiation-estrogen-induced mammary cancer in the rat. Country unknown/Code not available: N. p., 1973. Web.
Segaloff, A. Inhibition by progesterone of radiation-estrogen-induced mammary cancer in the rat. Country unknown/Code not available.
Segaloff, A. Tue . "Inhibition by progesterone of radiation-estrogen-induced mammary cancer in the rat". Country unknown/Code not available. doi:.
@article{osti_4365356,
title = {Inhibition by progesterone of radiation-estrogen-induced mammary cancer in the rat},
author = {Segaloff, A.},
abstractNote = {The data from this preliminary experiment make it appear that continuous administration of progesterone protects animals from the synergism between estrogen and radiation. However, it also appears that the progesterone has by itself a protective effect against the individual carcinogenic agents since fewer tumors occurred on the opposite side as well as on the radiated side. In this preliminary experiment none of the animals that bore just progesterone pellets and were radiated developed mammary carcinomata. (auth)},
doi = {},
journal = {Cancer Res., v. 33, no. 5, pp. 1136-1137},
number = ,
volume = ,
place = {Country unknown/Code not available},
year = {Tue May 01 00:00:00 EDT 1973},
month = {Tue May 01 00:00:00 EDT 1973}
}
  • Both sexes of inbred WF rats at either 8 or 28-60 weeks of age were exposed to 200 rad whole-body radiation, 2.5 or 5.0 mg 17 beta-estradiol (E2), or both agents The female rats treated with E2 alone or with both X-rays and E2 at 8 weeks of age showed a high incidence of mammary carcinomas (MCA), a large increase in pituitary weight, and a rise in serum prolactin (PRL) levels. However, the same treatments to males did not induce MCA despite a moderate increase in both pituitary weight and serum PRL. Ovariectomy prior to E2 treatment failed to modifymore » the occurrence of MCA or pituitary tumors. When X-rays and E2 were given to female rats at 28-60 weeks of age, pituitary weight, serum PRL levels, and the incidence of MCA were unaffected. When the E2 pellet was kept for the first 24 weeks and withdrawn during the last 12 weeks, the incidence of MCA, pituitary weight, and serum PRL was low. It was concluded that: 1) the pituitary glands of young female rats were susceptible to E2 treatment but were insensitive in older females, and 2) the occurrence of MCA in female rats appeared to be promoted by elevated PRL levels secreted by E2-induced pituitary tumors. Mammary tissue of male rats was less sensitive to PRL levels in the development of MCA.« less
  • Young adult female rats of either the Sprague--Dawley stock or the ACI strain were each given an implant of a compressed pellet of 5 mg diethylstilbestrol (DES) and 15 mg cholesterol 2 days before irradiation with 0.4, 1.3, or 4.0 rads of 0.43-MeV neutrons. These rats were studied, along with appropriate irradiated and nonirradiated controls, until death or for a maximum of 48 weeks. Response differences between the strain and stock included the following: DES produced both pituitary tumors and mammary adenocarcinomas (MAC) only. Neutron radiation increased mammary fibroadenoma (MFA) formation in Sprague--Dawley rats only. No interactions between DES andmore » radiation on MAC formation in Sprague--Dawley rats. However, when DES and neutron radiation were combined, DES appeared to inhibit the MFA response to radiation in Sprague--Dawley rats. In contrast, DES appeared to act synergistically with neutron radiation on MAC formation in ACI rats. These results clearly demonstrate rat differences in mammary gland carcinogenesis in response to estrogen, to radiation, or to a combination of both agents.« less
  • No abstract prepared.
  • Metabolic changes following estrogen stimulation and the inhibition of these changes in the presence of actinomycin D and cycloheximide were monitored continuously in perfused human breast cancer T47D clone 11 cells with {sup 31}P and {sup 13}C NMR techniques. The experiments were performed by estrogen rescue of tamoxifen-treated cells. Immediately after perfusion with estrogen-containing medium, a continuous enhancement in the rates of glucose consumption, lactate production by glycolysis, and glutamate synthesis by the Krebs cycle occurred with a persistent 2-fold increase at 4 hr. Pretreatment with either actinomycin D or cycloheximide, at concentrations known to inhibit mRNA and protein synthesis,more » respectively, and simultaneous treatment with estrogen and each inhibitor prevented the estrogen-induced changes in glucose metabolism. This suggested that the observed estrogen stimulation required synthesis of mRNA and protein. These inhibitors also modulated several metabolic activities that were not related to estrogen stimulation. The observed changes in the in vivo kinetics of glucose metabolism may provide a means for the early detection of the response of human breast cancer cells to estrogen versus tamoxifen treatment.« less